tradingkey.logo

Australia's Orthocell rises on regulatory nod to begin sales in Canada

ReutersApr 30, 2025 1:02 AM

Shares of Orthocell Ltd OCC.AX rise 3.8% to A$1.52, their highest since April 10

The biotech firm receives regulatory approval from Health Canada to commence sales of its flagship nerve repair product Remplir in Canadian market

Co says first sales expected in the second half of 2025

Stock up 11.1% YTD, including moves in the current session

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI